OCT 2 4 2005

**CENTRAL FAX CENTER** 

F000	,	F 1 Or 3 (02-04
		07/31/2006. OMB 0651-003
U.S. Patent and	Trademark Office: U.S. DEI	PARTMENT OF COMMERC

	Application N				Hexa II	displays a valid OMB control number.		
TRANSMITTAL	. Filing Date	10/007,4 Filing Date 11/07/20						
FORM	First Named	Inventor	11/07/2001					
FORM	Art Unit		David L. Lewis					
·	Examiner Na	me	1635					
(to be used for all correspondence after initial	iling)		Gibbs, Terra C.					
Total Number of Pages in This Submission	10 Attorney Doc	ket Number	Mirus.030.04					
ENCLOSURES (Check all that apply)								
Fee Transmittal Form Fee Attached	Drawing(s)  Licensing-related Papers			After Allowance Communication to TC  Appeal Communication to Board of Appeals and Interferences				
Amendment/Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority Document(s)  Reply to Missing Parts/ Incomplete Application  Reply to Missing Parts  under 37 CFR 1.52 or 1.53	Petition Petition to Conv Provisional App Power of Attorn Change of Corr Terminal Discla Request for Ref CD, Number of Landscap Remarks Reply to office ac	lication ey, Revocation espondence Ad imer fund CD(s) e Table on CD	ddress		(Appea Proprio Status	I Communication to TC Il Notice, Brief, Reply Brief) stary Information Letter Enclosure(s) (please identify ):		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT								
Firm Name Mirus Bio Corpora	tion							
Signature File &_								
Printed name Kirk Ekena								
Date 10/24/2005		Reg. No.			56,672			
CERTIFICATE OF TRANSMISSION/MAILING								
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:								
Signature Ril A								
Typed or printed name Kirk Ekena				. [	Date	10/24/2005		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

## RECEIVED **CENTRAL FAX CENTER**

OCT 2 4 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10/007,459 Appl. No.

Confirmation No. 3774

**Applicants** 

David L. Lewis et al.

Filed

11/07/2001

Art Unit

1635

Examiner

Gibbs, Terra C.

Docket No.:

Mirus.030.04

For: Inhibition Of Gene Expression By Delivery Of Small Interfering RNA To Post-

Embryonic Animal Cells In vivo

Commissioner of Patents PO Box 1450 Alexandria, VA 22313-1450

## AMENDMENT UNDER 37 C.F.R. § 1.111

## Dear Commissioner:

This Amendment responds to the Office Action dated August 24, 2005. Kindly amend the application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 4 of this paper.

An Appendix including a Replacement Sheet to the specification and Terminal Disclaimers is attached following page 6 of this paper.